Focus: Fosun Pharma is a publicly listed diagnostics and specialty pharma company headquartered in Sydney, Australia, with a diversified portfolio spanning oncology, neurology, cardiovascular, infectious disease, and respiratory therapeutic areas.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Fosun Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Fosun Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fosun Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship revenue driver representing 24% of company revenue with 11-year patent runway.
Significant post-LOE generic with moderate Medicare exposure; demonstrates generic competency but limited growth upside.
Branded version of abiraterone extending LOE to 2034; secondary franchise driver with moderate Medicare uptake.
Hedgehog pathway inhibitor in oncology/rare disease with 10-year patent protection; specialized but niche indication.
Mature bisphosphonate generic with stable but eroding Medicare reimbursement in competitive osteoporosis category.
183 discontinued, 106 duplicate formulations not shown
+3 more products with revenue data
Fosun gains clinical trial approval in China for FXB-0871 - BioWorld News
Fosun gains clinical trial approval in China for FXB-0871 BioWorld News
Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871 - The Globe and Mail
Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871 The Globe and Mail
FOSUN PHARMA (02196.HK): Subsidiary's FXB0871 Approved for Clinical Trials in Mainland China - AASTOCKS.com
FOSUN PHARMA (02196.HK): Subsidiary's FXB0871 Approved for Clinical Trials in Mainland China AASTOCKS.com
Fosun Pharma (600196.SH): Venlafaxine Hydrochloride Sustained-Release Tablets received acceptance of pharmaceutical registration application. - 富途牛牛
Fosun Pharma (600196.SH): Venlafaxine Hydrochloride Sustained-Release Tablets received acceptance of pharmaceutical registration application. 富途牛牛
Citi Keeps Their Buy Rating on Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) - The Globe and Mail
Citi Keeps Their Buy Rating on Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) The Globe and Mail
Fosun Pharma Lifts 2025 Profit on Higher Margins and EBITDA - The Globe and Mail
Fosun Pharma Lifts 2025 Profit on Higher Margins and EBITDA The Globe and Mail
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Rationalizing nose-to-brain drug delivery: Machine learning-guided optimization and mechanistic elucidation of olfactory deposition for nasal sprays.
Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials.
+77 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo